Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$0.03
+1.7%
$0.03
$0.02
$0.06
$5.54M0.47164,486 shs790,314 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.31
-4.6%
$3.17
$2.57
$6.88
$20.45M0.639,065 shs10,288 shs
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$0.05
+6.9%
$0.06
$0.02
$0.07
$18.99M-0.6655,461 shs47,775 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$0.31
+4.9%
$0.30
$0.24
$1.47
$22.07M0.08416,079 shs489,820 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.00%+1.69%+14.07%-7.69%-48.72%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-4.31%-0.90%-14.91%-46.61%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00%-5.67%-24.60%-13.38%+36.06%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.00%+10.78%+8.27%-26.98%-60.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4.5149 of 5 stars
3.63.00.04.63.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00
N/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3.20
Buy$3.13906.77% Upside

Current Analyst Ratings Breakdown

Latest CVSI, OVID, NAII, and OTLC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.00 ➝ $1.50
4/24/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/24/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$15.70M0.35N/AN/A$0.01 per share3.00
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.18N/AN/A$13.32 per share0.25
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$70K271.80$0.01 per share9.06$0.02 per share2.33
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$570K38.72N/AN/A$0.96 per share0.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CV Sciences, Inc. stock logo
CVSI
CV Sciences
-$2.39M-$0.01N/AN/A-12.25%-89.43%-22.75%N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
-$4.52M-$0.01N/AN/AN/A-14.16%-4.41%N/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)

Latest CVSI, OVID, NAII, and OTLC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.26
1.14
0.30
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/A
0.01
0.01
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.22
4.93
4.93

Institutional Ownership

CompanyInstitutional Ownership
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
CV Sciences, Inc. stock logo
CVSI
CV Sciences
70184.79 million177.77 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
20408.29 million248.16 millionNot Optionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
6071.11 million61.80 millionOptionable

Recent News About These Companies

Ovid Therapeutics (OVID) Receives a Buy from TD Cowen
Ovid Therapeutics price target lowered to $4 from $5 at BTIG
William Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CV Sciences stock logo

CV Sciences OTCMKTS:CVSI

$0.03 +0.00 (+1.69%)
As of 06/20/2025 03:44 PM Eastern

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.35 -0.12 (-3.34%)
As of 06/20/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Oncotelic Therapeutics stock logo

Oncotelic Therapeutics OTCMKTS:OTLC

$0.05 +0.00 (+6.88%)
As of 06/20/2025 03:57 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.31 +0.01 (+4.90%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$0.31 +0.00 (+0.19%)
As of 06/20/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.